共查询到20条相似文献，搜索用时 46 毫秒
1.
在现代医学中，心血管病学是内科学的一个重要组成部分，在20世纪20年代逐渐形成独立的学科，1628年，Harvey发现血液循环。1733年，Hales测量动脉血压，奠定了心血管生理学基础。1768年Heberden和1772年Jenner对心绞痛的描述和病因的确定开创了临床诊断心血管病的先河。1819年，Laennec发明听诊器，提供了最早用于诊断心血管病的仪器。1785年，Withering用洋地黄治疗心力衰竭，提供了最早治疗心血管病的手段。近百年来，心血管病学取得了长足进步，近50年的发展尤其迅速。 相似文献
2.
《心血管病学进展》是心血管病学专业性医学杂志,也是介绍国内和国外心血管病学及有关学科最新进展的学术刊物。本刊为中国科技论文统计源期刊(中国科技核心期刊)、首届全国中文核心期刊和四川省优秀期刊,并被多家数据库收录。本刊宗旨是为发展中国医药卫生事业,促进国内外心血管病学的学术交流,不断提高对心血管疾病的诊断、治疗和学术水平,以实用为主,面向临床,把为临床医师服务放在首位,并为从事心血管疾病防治的科研、教学和医学院校师生服务。 相似文献
3.
《心血管病学进展》是心血管病学专业性医学杂志,也是介绍国内和国外心血管病学及有关学科最新进展的学术刊物。本刊为中国科技论文统计源期刊(中国科技核心期刊)、首届全国中文核心期刊和四川省优秀期刊,并被多家数据库收录。本刊宗旨是为发展中国医药卫生事业,促进国内外心血管病学的学术交流,不断提高对心血管疾病的诊断、治疗和学术水平,以实用为主,面向临床,把为临床医师服务放在首位,并为从事心血管疾病防治的科研、教学和医学院校师生服务。 相似文献
4.
5.
6.
7.
《心血管病学进展》2006,27(1):119-120
《心血管病学进展》是心血管病学专业性医学杂志,也是介绍国内和国外心血管病学及有关学科最新进展的学术刊物。本刊为首届全国中文核心期刊和四川省优秀期刊,2005年被收录入中国科技论文统计源期刊(中国科技核心期刊)。本刊宗旨是为发展我国医药卫生事业,促进国内外心血管病学的学术交流,不断提高对心血管疾病的诊断、治疗和学术水平,以实用为主,面向临床,把为临床医师服务放在首位,并为从事心血管疾病防治的科研、教学和医学院校师生服务。有综述、译文(节译、文摘)、讲座、述评、编译等栏目。主要读者对象为心血管临床医师及防治科研人员,以及医学院校师生教学和学习参考,对基层医务工作者尤为适宜。热忱欢迎广大医药卫生工作者踊跃投稿。1稿约范围本刊以“综述”为主,内容以临床实用为主,并适当刊登与临床有关的基础理论研究性综述文章。要求能及时反映国内和国外在心血管病学及有关学科方面的最新理论、新研究成果、新药及新诊疗技术等内容文章。综述、讲座、述评、编译等文章5 000字以内为宜,译文的节译在3 000字以内为宜,文摘在1 000字以内为宜。译文的节译和文摘限近3-6个月内国外发表的综述(作节译)和其他形式(作文摘)的文章,请阅读原文后选译结合临床有实用指导意义的内容,请勿直接翻译原文稿的摘要作文摘。节译和文摘的来稿,必须附上外文原稿。2来稿要求2．1文题：力求简明、醒目,反映出文章的主题。中文文题以20个汉字以内为宜,英文文题不宜超过10个实词,中英文文题含义应一致,题名中应避免使用非公知公认的缩略语、字符、代号及结构式和公式。2．2作者：请标明作者及审校者,并写出姓名的汉语拼音、中英文单位名称、详细地址(包括省、市、县)、邮政编码等。 相似文献
8.
9.
10.
<正>《心血管病学进展》是心血管病学专业性医学杂志,也是介绍国内和国外心血管病学及有关学科最新进展的学术刊物。本刊为中国科技论文统计源期刊(中国科技核心期刊)、首届全国中文核心期刊和四川省优秀期刊,并被多家数据库收录。本刊宗旨是为发展中国医药卫生事业,促进国内外心血管病学的学术交流,不断提高对心血管疾病的诊断、治疗和学术水平,以实用为主,面向临床,把为临床医师服务放在首位,并为从事心血管疾病防治的科研、教学和医学院校师生服务。 相似文献
11.
12.
Rapamycin in cardiovascular medicine 总被引：12，自引：0，他引：12
Abstract
The cellular action of rapamycin (sirolimus), a natural fermentation product produced by Streptomyces hygroscopicus , is mediated by binding to the FK506 binding protein. By inhibiting a kinase known as the target of rapamycin, it restricts the proliferation of smooth-muscle cells by blocking cell-cycle progression at the G1/S transition.
The finding that rapamycin possesses both antiproliferative and antimigratory activity suggests that it could contribute to the control of arterial re-narrowing after percutaneous intervention and control the vascular manifestations of chronic rejection in transplanted hearts.
The first clinical trials of implantation of rapamycin-coated stents in obstructive coronary artery lesions have been reported and, in selected patient groups, it appears that the restenosis process has been abolished. Studies are underway to establish the benefits of rapamycin-coated stents in day-to-day interventional practice, including small vessels, long lesions and patients with multivessel disease. With the addition of novel antiplatelet agents and delivery systems, it is possible that the two major limitations of percutaneous coronary intervention − restenosis and stent thrombosis − will be overcome.
Cardiac graft loss due to intimal hyperplasia and accelerated atherosclerosis remains the major limitation to long-term survival following cardiac transplantation. Animal studies of rapamycin have suggested that this process can be reduced or abolished. Human studies of the efficacy of rapamycin in preventing both acute rejection and allograft arterial disease are in progress.
Concerns regarding toxicity, carcinogenicity, delayed healing and endothelialization remain. As with any new agent or technology, we must remain vigilant to late adverse side-effects. (Intern Med J 2003; 33: 103−109) 相似文献
The cellular action of rapamycin (sirolimus), a natural fermentation product produced by Streptomyces hygroscopicus , is mediated by binding to the FK506 binding protein. By inhibiting a kinase known as the target of rapamycin, it restricts the proliferation of smooth-muscle cells by blocking cell-cycle progression at the G1/S transition.
The finding that rapamycin possesses both antiproliferative and antimigratory activity suggests that it could contribute to the control of arterial re-narrowing after percutaneous intervention and control the vascular manifestations of chronic rejection in transplanted hearts.
The first clinical trials of implantation of rapamycin-coated stents in obstructive coronary artery lesions have been reported and, in selected patient groups, it appears that the restenosis process has been abolished. Studies are underway to establish the benefits of rapamycin-coated stents in day-to-day interventional practice, including small vessels, long lesions and patients with multivessel disease. With the addition of novel antiplatelet agents and delivery systems, it is possible that the two major limitations of percutaneous coronary intervention − restenosis and stent thrombosis − will be overcome.
Cardiac graft loss due to intimal hyperplasia and accelerated atherosclerosis remains the major limitation to long-term survival following cardiac transplantation. Animal studies of rapamycin have suggested that this process can be reduced or abolished. Human studies of the efficacy of rapamycin in preventing both acute rejection and allograft arterial disease are in progress.
Concerns regarding toxicity, carcinogenicity, delayed healing and endothelialization remain. As with any new agent or technology, we must remain vigilant to late adverse side-effects. (Intern Med J 2003; 33: 103−109) 相似文献
13.
14.
15.
Cardiovascular medicine is changing rapidly with the development, testing, and introduction of new diagnostic and therapeutic methods. New interventional techniques such as the use of drug-eluting stents have important implications for the care of individual patients and the delivery and economics of health care in general. Drug-eluting stents have been shown to improve outcomes among patients undergoing percutaneous coronary intervention by significantly reducing restenosis rates. Two randomized trials have documented that per 100 patients treated with the sirolimus drug-eluting stent, 12.5 to 13.6 patients avoided the need for subsequent target lesion revascularization, when compared with patients treated with conventional stents. The economic effect of the introduction of these stents, which are projected to be two to three times as expensive as conventional stents, is complex and depends on which segment of health care is considered. These stents will be favorably received by patients, physicians, employers, and society as well as payers. However, hospitals may be adversely affected by having increased procedural costs for the stents, along with fewer procedures for evaluation and treatment of restenosis and probably decreased surgical volumes. Drug-eluting stents are only the first of many new technologic advances that will affect cardiovascular care. These procedures have many features in common, including: 1). replacement of major surgical procedures with less invasive approaches; and 2). redistribution of costs, with a decrease in hospital profits but potentially lower costs of health care delivery for society as a whole. 相似文献
16.
17.
18.
Bartecchi CE 《Journal of the American College of Cardiology》2006,47(7):1498-9; author reply 1499-500
19.
20.
<正>2011年心血管领域公布了多个临床研究结果,与此同时,一些重要指南的更新,又为老年心血管疾病诊治提供了依据。我们对2011年老年心血管领域重要研究或进展进行总结。1高血压领域2010年中国高血压防治指南[1]和新公布的2011年老年高血压的诊断与治疗中国专家共识[2]对老年人的降压治疗提出了具体指导意见。基于现有临床证据,推荐将血压<150/90 mm Hg作为老年 相似文献